My recent work has shown that novel dual Syk-PI3Kγ inhibitor SRX3207 effectively relieves tumor immunosuppression in solid tumors [211] and has shown great efficacy in targeting immunosuppressive TME of NB (data unpublished). Here, SYK is linked to neoplasm.